Boron Compound Active Ingredients TRIZ Cases
- BCMAxCD3 and Anti-CD38 Antibodies for T Cell Exhaustion
Combining BCMAxCD3 and anti-CD38 antibodies restores T cell activity in multiple myeloma and improves tumor cell killing.
- Selective HDAC6 Inhibitors for Lower-Toxicity Cancer Sensitization
Selective HDAC6 inhibitors improve isoform specificity to reduce off-target toxicity while increasing cancer cell sensitivity to radiotherapy and chemotherapy.
- Arginase Inhibitor Compounds for Restoring Tumor L-Arginine
Selective arginase inhibitors restore tumor L-arginine levels to boost T-cell activation while limiting off-target effects and translation complexity.
- Anti-CD38 Combination Therapy for High-Risk Multiple Myeloma
Combining an anti-CD38 antibody, corticosteroid, and chemotherapy helps overcome drug resistance, improve remission, and reduce relapse risk.
- Heparanase-Neutralizing A54 Antibody for Specific Enzyme Inhibition
A54 targets the HBD-II region of heparanase to block enzymatic activity and cell invasion while avoiding off-target effects of less specific inhibitors.
- Selective Immunoproteasome Inhibitors for Lower-Side-Effect Therapy
Selective LMP7 and LMP2 inhibition preserves therapeutic efficacy while reducing side effects linked to non-selective proteasome blockers.
- Selective TEAD Inhibitors for Blocking YAP-TAZ Tumor Signaling
Small-molecule TEAD inhibitors disrupt YAP-TAZ binding to curb tumor growth while limiting off-target effects and preserving normal cell functions.
- Cancer Combination Therapy Using CDK and BCL-2 Inhibitors
Combining a CDK inhibitor with a BCL-2 or proteasome inhibitor improves anti-cancer response by boosting apoptosis and overcoming drug resistance.
- c-Myc Inhibitor Scaffold for Drug-Resistant Cancer Therapy
Novel Formula I compounds selectively inhibit c-Myc, addressing drug resistance and limited treatment effectiveness in cancer and related diseases.
- Boronic Acid Proteasome Inhibitors With Reversible Selective Binding
Reversible boronic acid binding selectively inhibits chymotrypsin-like proteasome activity, reducing side effects and resistance risk.
- BCMA Combination Therapy Regimen for Transplant-Ineligible Myeloma
A four-drug BCMA-based regimen improves survival and minimal residual disease negativity in transplant-ineligible newly diagnosed myeloma.
- Immuno-DASH and PGE2 Antagonist Combination for Dose-Limited Cancer Therapy
Combining immuno-DASH inhibitors with PGE2 antagonists raises tolerated dose and antitumor immune response while reducing toxicity.
- Multifunctional Hydrogel Barrier for Postoperative Adhesion Prevention
An injectable hyaluronic acid hydrogel forms a wet-surface barrier while reducing oxidative stress and inflammation to limit postoperative adhesions.